Month: September 2022

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

09/13/2022

Company Expects Phase 2 Data with Second Drug Candidate (CST-103) in Neurodegenerative Diseases in Third Quarter of 2022 Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032,…

Read More

NaNotics to Collaborate with Mass General Cancer Center (MGCC) on Novel Nanomedicine for Treating Cancer

09/13/2022

The goal is first-in-human use of NaNots™, injectable absorptive nanoparticles that treat cancer via clearance of tumor-generated immune inhibitors from blood. Excerpt from the Press Release: MILL VALLEY, Calif.–(BUSINESS WIRE)–NaNotics LLC, a biopharmaceutical company developing NaNots™, novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration…

Read More

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

09/13/2022

— Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 — — Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 — —…

Read More

Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System

09/12/2022

Expected to Accelerate Sales Opportunities in Doctor’s Office and Wound Clinics Excerpt from the Press Release: FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it has launched a multi-site clinical study…

Read More

Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2

09/12/2022

Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants…

Read More

2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients

09/12/2022

This study will evaluate Abecma in patients with suboptimal response to transplant Data from KarMMa-3 and KarMMa-2 studies of Abecma will be presented at future medical meeting Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed…

Read More

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

09/09/2022

Findings presented at the European Respiratory Society International Congress 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease…

Read More

Biotechnology Company Purissima Releases Study Findings Related to the Potential Applications and Usage of Cannabichromene (CBC)

09/09/2022

Study’s Results Reveal CBC’s Robust Therapeutic Properties to Help Contribute to Skin Health Excerpt from the Press Release: SAN FRANCISCO, Sept. 8, 2022 /PRNewswire/ — Purissima, a leading biotechnology health and wellness company, announced the completion of two separate ingredient testing programs with two leading contract research organizations. Testing included biological tests on human skin…

Read More

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

09/09/2022

– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 months with nivolumab combined with ipilimumab – Excerpt from the Press…

Read More

Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing Head and Neck Surgery

09/06/2022

ALM-488 is a peptide-dye conjugate designed to fluorescently highlight nerves in real time during surgery Excerpt from the Press Release: LA JOLLA, Calif., Aug. 23, 2022 /PRNewswire/ — Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, today announced that the first patient has been dosed in a Phase 3 pivotal…

Read More